Hepatocyte CEBPA-ORM1 axis restricts alcohol-associated liver disease

Area of Science:

• Hepatology
• Molecular Biology
• Genetics

Background:

• Alcohol-associated liver disease (ALD) is a significant health issue with few treatments.
• The role of hepatocyte transcription factor CCAAT/enhancer-binding protein α (CEBPA) in ALD is not well understood.
• This study investigates CEBPA's function in alcohol-induced liver steatosis and ALD.

Purpose of the Study:

• To determine the role of hepatocyte CEBPA in the pathogenesis of alcohol-associated liver disease.
• To identify downstream targets of CEBPA involved in ALD.
• To explore the therapeutic potential of the CEBPA-ORM1 axis in ALD.

Main Methods:

• Utilized hepatocyte-specific CEBPA knockout mice and acute/chronic ALD models.
• Performed AAV transduction studies, reporter gene assays, and Western blotting on human ALD liver tissues.
• Conducted global transcriptomics and chromatin immunoprecipitation to identify CEBPA targets.

Main Results:

• Hepatic CEBPA expression decreased in human ALD patients and its loss exacerbated alcohol-induced steatosis in mice.
• CEBPA directly upregulates orosomucoid 1 (ORM1) transcription, and loss of ORM1 worsened ALD.
• Restoring CEBPA or ORM1 ameliorated liver steatosis and reduced ALD progression; serum ORM1 correlated inversely with ALD severity.

Conclusions:

• The hepatocyte CEBPA-ORM1 axis is a key suppressor of alcohol-associated liver disease.
• This axis presents potential therapeutic targets for ALD.
• Serum ORM1 may serve as a biomarker for assessing ALD severity.